JP2006513149A - Ｂａｃｉｌｌｕｓａｎｔｈｒａｃｉｓを迅速かつ特異的に検出および殺滅するファージ関連溶菌酵素の同定 - Google Patents

Ｂａｃｉｌｌｕｓａｎｔｈｒａｃｉｓを迅速かつ特異的に検出および殺滅するファージ関連溶菌酵素の同定 Download PDF

Info

Publication number
JP2006513149A
JP2006513149A JP2004538165A JP2004538165A JP2006513149A JP 2006513149 A JP2006513149 A JP 2006513149A JP 2004538165 A JP2004538165 A JP 2004538165A JP 2004538165 A JP2004538165 A JP 2004538165A JP 2006513149 A JP2006513149 A JP 2006513149A
Authority
JP
Japan
Prior art keywords
lytic enzyme
enzyme
sequence
bacillus anthracis
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004538165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006513149A5 (https=
Inventor
ビンセント エー． フィッシェティ，
レイモンド シュック，
ダニエル ネルソン，
ローレンス ルーミス，
デイビッド トゥルーディル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockefeller University filed Critical Rockefeller University
Publication of JP2006513149A publication Critical patent/JP2006513149A/ja
Publication of JP2006513149A5 publication Critical patent/JP2006513149A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/32—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Bacillus (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
JP2004538165A 2002-05-17 2003-05-19 Ｂａｃｉｌｌｕｓａｎｔｈｒａｃｉｓを迅速かつ特異的に検出および殺滅するファージ関連溶菌酵素の同定 Pending JP2006513149A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38087502P 2002-05-17 2002-05-17
PCT/US2003/015719 WO2004027020A2 (en) 2002-05-17 2003-05-19 Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis

Publications (2)

Publication Number Publication Date
JP2006513149A true JP2006513149A (ja) 2006-04-20
JP2006513149A5 JP2006513149A5 (https=) 2008-02-14

Family

ID=32030583

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004538165A Pending JP2006513149A (ja) 2002-05-17 2003-05-19 Ｂａｃｉｌｌｕｓａｎｔｈｒａｃｉｓを迅速かつ特異的に検出および殺滅するファージ関連溶菌酵素の同定

Country Status (6)

Country Link
US (2) US7402309B2 (https=)
EP (1) EP1501925A4 (https=)
JP (1) JP2006513149A (https=)
AU (1) AU2003291614A1 (https=)
CA (1) CA2486280A1 (https=)
WO (1) WO2004027020A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101339908B1 (ko) 2011-11-11 2013-12-10 가천대학교 산학협력단 바실러스 세레우스에 대해 생육 억제능을 나타내는 신규의 박테리오파지
JP2016515609A (ja) * 2013-04-02 2016-05-30 テミス メディケア リミティド ジエチレングリコールモノエチルエーテル又は他のアルキル誘導体を含む医薬活性成分の組成物
KR101765393B1 (ko) 2015-11-05 2017-08-07 국방과학연구소 탄저균 특이 용균 단백질 b4의 제조 방법 및 탄저균에 의해 유발되는 질환의 치료 방법

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040172667A1 (en) * 2002-06-26 2004-09-02 Cooper Richard K. Administration of transposon-based vectors to reproductive organs
US7527966B2 (en) * 2002-06-26 2009-05-05 Transgenrx, Inc. Gene regulation in transgenic animals using a transposon-based vector
US8071364B2 (en) * 2003-12-24 2011-12-06 Transgenrx, Inc. Gene therapy using transposon-based vectors
RU2296576C2 (ru) * 2005-05-18 2007-04-10 Институт биохимии и физиологии микроорганизмов им. Г.К. Скрябина РАН СРЕДСТВО, ОБЛАДАЮЩЕЕ БАКТЕРИЦИДНЫМ ДЕЙСТВИЕМ В ОТНОШЕНИИ ВЕГЕТАТИВНЫХ И СПОРОВЫХ КЛЕТОК Bacillus anthracis, СПОСОБ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СИБИРСКОЙ ЯЗВЫ
WO2008018854A2 (en) * 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
CA2620903A1 (en) * 2005-08-24 2007-03-01 The Rockefeller University Ply-gbs mutant lysins
CN100395341C (zh) * 2006-03-09 2008-06-18 中国人民解放军军事医学科学院生物工程研究所 一种表达炭疽杆菌γ噬菌体裂解酶的方法及其专用基因
DE102006061002A1 (de) 2006-12-22 2008-06-26 Profos Ag Verfahren und Mittel zur Anreicherung, Entfernung und zum Nachweis von gram-positiven Bakterien
US20110059514A1 (en) * 2007-01-09 2011-03-10 David Alexander Schofield Yeast Biocatalysts for Degradation of Biowarfare Agents
CN101003569B (zh) * 2007-01-19 2010-06-23 中国人民解放军军事医学科学院生物工程研究所 炭疽杆菌γ噬菌体裂解酶抗原表位及其突变体与应用
CA2699451A1 (en) * 2007-06-15 2009-04-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine , Inc. Bacteriophage with enhanced lytic activity
WO2009082525A2 (en) 2007-10-01 2009-07-02 Guild Associates, Inc. Differentially fluorescent yeast biosensors for the detection and biodegradation of chemical agents
JP2011518543A (ja) 2008-01-10 2011-06-30 トラスティーズ オブ ボストン ユニバーシティ 抗微生物剤のための佐剤としての改変バクテリオファージならびにその組成物および使用方法
WO2010036976A2 (en) * 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of antibodies
WO2010036978A2 (en) * 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of growth hormone
US20100081789A1 (en) * 2008-09-25 2010-04-01 Cooper Richard K Novel Vectors for Production of Interferon
CA2744909A1 (en) 2008-11-28 2010-06-03 Warren H. Finlay Bacteriophage compositions for treatment of bacterial infections
WO2010141135A2 (en) 2009-03-05 2010-12-09 Trustees Of Boston University Bacteriophages expressing antimicrobial peptides and uses thereof
US9150881B2 (en) * 2009-04-09 2015-10-06 Proteovec Holding, L.L.C. Production of proteins using transposon-based vectors
CA2833409A1 (en) 2011-04-21 2012-10-26 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
EP2764093B1 (en) 2011-10-05 2018-04-18 The Rockefeller University Dimeric bacteriophage lysins
KR20210121313A (ko) 2012-05-09 2021-10-07 콘트라펙트 코포레이션 그람 양성 박테리아에 대한 박테리오파지 리신과 항생제의 병용물
KR20200023521A (ko) 2012-05-09 2020-03-04 콘트라펙트 코포레이션 박테리오파지 리신을 이용한 생물막의 예방, 붕괴 및 치료
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
KR20190004799A (ko) 2016-05-12 2019-01-14 콘트라펙트 코포레이션 항균 폴리펩티드의 최소 억제 농도를 평가 및 탐지하기 위한 배지미량희석법
WO2019013781A1 (en) 2017-07-12 2019-01-17 Ecolab Usa Inc. METHOD FOR RAPID DETECTION OF BACTERIAL SPORES IN AN INDUSTRIAL PROCESS
EP3652330B1 (en) * 2017-07-12 2025-04-30 Ecolab USA Inc. RAPID APPROACH FOR THE DETECTION OF BACTERIAL SPORES
KR102146555B1 (ko) * 2018-11-27 2020-08-20 국방과학연구소 탄저균 특이적 항균능을 갖는 약학적 조성물 및 이의 제조방법
WO2021092362A1 (en) 2019-11-07 2021-05-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of specific phages for the treatment of nontuberculous mycobacteria (ntm) infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US127215A (en) * 1872-05-28 Improvement in chemical compounds for destroying nicotine in tobacco
US6329156B1 (en) * 1999-03-22 2001-12-11 The Regents Of The University Of California Method for screening inhibitors of the toxicity of Bacillus anthracis
US20020127215A1 (en) * 1999-09-14 2002-09-12 Lawrence Loomis Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
GB0118009D0 (en) * 2001-07-24 2001-09-19 Regma Biotechnologies Ltd Novel preparation

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101339908B1 (ko) 2011-11-11 2013-12-10 가천대학교 산학협력단 바실러스 세레우스에 대해 생육 억제능을 나타내는 신규의 박테리오파지
JP2016515609A (ja) * 2013-04-02 2016-05-30 テミス メディケア リミティド ジエチレングリコールモノエチルエーテル又は他のアルキル誘導体を含む医薬活性成分の組成物
KR101765393B1 (ko) 2015-11-05 2017-08-07 국방과학연구소 탄저균 특이 용균 단백질 b4의 제조 방법 및 탄저균에 의해 유발되는 질환의 치료 방법

Also Published As

Publication number Publication date
EP1501925A4 (en) 2006-10-25
AU2003291614A8 (en) 2004-04-08
US20120164124A1 (en) 2012-06-28
EP1501925A2 (en) 2005-02-02
WO2004027020A3 (en) 2004-12-02
WO2004027020A9 (en) 2004-05-21
CA2486280A1 (en) 2004-04-01
WO2004027020A2 (en) 2004-04-01
US7402309B2 (en) 2008-07-22
US8580553B2 (en) 2013-11-12
AU2003291614A1 (en) 2004-04-08
US20050004030A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
US8580553B2 (en) Phage-associated lytic enzymes for treatment of Bacillus anthracis and related conditions
JP6735796B2 (ja) グラム陽性細菌を検出および処置するためのＳｔｒｅｐｔｏｃｏｃｃｕｓバクテリオファージリシン
US7582291B2 (en) Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
US20140179594A1 (en) Streptococcus bacteriophage lysins for treatment of gram positive bacteria in companion animals and livestock
US7569223B2 (en) Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
AU2018203076B2 (en) Dimeric bacteriophage lysins
US8389469B2 (en) Bacteriophage lysins for Bacillus anthracis
US8105585B2 (en) Ply-GBS mutant lysins
WO2003024410A2 (en) Composition for treating streptococcus pneumoniae
US20020136712A1 (en) Bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of colonization and infections caused by streptococcus pneumoniae

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060518

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100119